277 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Rank Status Study
1 Recruiting Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung
Interventions: Drug: recombinant human endostatin;   Drug: pemetrexed plus cisplatin or carboplatin
2 Terminated NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
3 Active, not recruiting The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Condition: Adenocarcinoma of Lung
Interventions: Biological: Cytokine-Induced Killer Cells;   Drug: Apatinib
4 Unknown  Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
Conditions: Lung Adenocarcinoma;   Breast Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma
Intervention: Other: their will be no intervention in any of the groups, the study is retrospective
5 Unknown  Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
6 Completed Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Conditions: Lung Adenocarcinoma;   Brain Metastases
Interventions: Drug: erlotinib;   Drug: pemetrexed;   Drug: cisplatin
7 Recruiting Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
8 Recruiting Telomere Biology in Early Adenocarcinoma of the Lung
Conditions: Adenocarcinoma of the Lung;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention:
9 Completed Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Conditions: Non-small-cell Lung Cancer;   Squamous Cell Carcinoma;   Adenocarcinoma of the Lung
Interventions: Drug: AXL1717;   Drug: Docetaxel
10 Unknown  The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
11 Not yet recruiting Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention: Drug: Erlotinib, Pemetrexed
12 Not yet recruiting Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
Conditions: Non-small Cell Lung Cancer Stage I;   Lung Adenocarcinoma
Interventions: Procedure: patients undergo cVATS segmentectomy;   Procedure: Patients undergo cVATS lobectomy
13 Completed
Has Results
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib with cetuximab
14 Not yet recruiting Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
Conditions: Lung Cancer;   Adenocarcinoma of the Lung
Interventions: Drug: Nivolumab;   Biological: GM.CD40L Vaccine
15 Recruiting A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
16 Recruiting Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Interventions: Biological: CIK;   Drug: chemotherapy
17 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
18 Not yet recruiting Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Condition: Lung Adenocarcinoma
Interventions: Drug: Apatinib (250 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (500 mg/d) + Docetaxel (60 mg/m2);   Drug: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
19 Completed A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: Farletuzumab;   Other: Placebo;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cisplatin
20 Recruiting Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
Condition: Stage IV Lung Adenocarcinoma
Interventions: Drug: Certolizumab;   Drug: cisplatin;   Drug: pemetrexed

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years